A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients with Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find the highest dose of the investigational drug ZEN003694 that can be given safely in men with metastatic castration-resistant prostate cancer (advanced cancer which has continued to grow despite hormonal therapy and in the absence of testosterone). It will be evaluated in men whose prostate cancer continued to grow after prior therapy that included abiraterone and/or enzalutamide.
ZEN003694 is designed to treat cancer by inhibiting a family of proteins called BET which enable prostate cancer cells to grow despite other treatments. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic castration-resistant prostate cancer that continued to grow despite prior therapy with abiraterone and/or enzalutamide.
- At least 2 weeks must pass between completion of previous treatments and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for men age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Wassim Abida at 646-422-4633.